<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="335061">
  <stage>Registered</stage>
  <submitdate>1/02/2010</submitdate>
  <approvaldate>3/02/2010</approvaldate>
  <actrnumber>ACTRN12610000117011</actrnumber>
  <trial_identification>
    <studytitle>The TOP study: The effect of Thermally Oxidised Polyunsaturated (TOP) fat on post-meal blood sugar levels in healthy participants.</studytitle>
    <scientifictitle>The effect of Thermally Oxidised Polyunsaturated fat on postprandial glycaemia in healthy participants.</scientifictitle>
    <utrn />
    <trialacronym>TOP</trialacronym>
    <secondaryid>nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Prevention of Type 2 diabetes</healthcondition>
    <healthcondition>Prevention of heart disease.</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Participants will be given a test meal of 40gm dried instant mash potato reconstituted with 160ml hot water, 50gm thermally oxidised  commercial sunflower oil, and 1500mg paracetamol. The paracetamol is added to enable the measurement of gastric emptying.
The thermally oxidised sunflower oil will have been prepared previously by heating the oil at 180 degrees centigrade for 6 hours and cooking potato chips from 2 potatoes every 30 minutes.
The washout period between meals is 1 week.</interventions>
    <comparator>The comparator is is identical to the intervention meal except that the sunflower oil is unheated (native).</comparator>
    <control>Active</control>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Measurements of plasma glucose, insulin, C-peptide, and non-estertfied fatty acids (NEFA) will made.</outcome>
      <timepoint>A fasting baseline blood sample and blood samples at timepoints of 10, 20, 30 60 , 90 and 120 minutes post-prandially.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Measurements of the incretin hormones glucagon-like polypeptide-1 (GLP-1), glucose-independant polypeptide (GIP) and triglycerides will also be made.</outcome>
      <timepoint>Baseline, 30, 60, 90 and 120 minutes.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Gastric emptying will be assesed by measurement of paracetamol in the blood after ingestion of paracetamol with the meal.</outcome>
      <timepoint>A fasting baseline blood sample and blood samples at timepoints of 30, 60, 90 and 120 minutes post-prandially.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>*Healthy subjects 
*Body mass index &gt;18kg/m2 and &lt;30 kg/m2</inclusivecriteria>
    <inclusiveminage>25</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>*Serious medical problems
*Use of some medications
*Fasting blood glucose &gt; 6.1 mmol/L
*Smokers</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Recruitment through newspaper advertisements and then telephone screening.
The treatment schedule will be held by an independant person.</concealment>
    <sequence>Subjects will be randomised to the order of meals using the second generator for crossover trials in the www. randomisation.com website.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>19/01/2010</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>26</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>University of Otago</primarysponsorname>
    <primarysponsoraddress>201 Great King Street
Dunedin 
9016</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>The National Heart Foundation of New Zealand</fundingname>
      <fundingaddress>9 Kalmia Street
Ellerslie
Auckland 1030</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Otago District Health Board</sponsorname>
      <sponsoraddress>201 Great King Street
Dunedin 9016</sponsoraddress>
      <sponsorcountry>New Zealand</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The study is comparing the effect of eating meals composed of thermally oxidised and native (unheated) polyunsaturated vegtable oil and carbohydrate on normal healthy people.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Lower South Regional Ethics Committee</ethicname>
      <ethicaddress>Ministry of Health
229 Moray Place
Dunedin
9016</ethicaddress>
      <ethicapprovaldate>27/11/2009</ethicapprovaldate>
      <hrec>LRS/09/10/045</hrec>
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Wayne Sutherland</name>
      <address>Department of Medical and Surgical Sciences
9th Floor 
Dunedin Hospital
201 Great King Street
Dunedin
9016</address>
      <phone>+64 3 4747007 ext.8512</phone>
      <fax>+64 3 4747641</fax>
      <email>Wayne.sutherland@otago.ac.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Patrick Manning</name>
      <address>Diabetes Department
Dunedin Hospital
201 Great King Street
Dunedin
9016</address>
      <phone>+64 3 4740999</phone>
      <fax>+64 3 470 9500</fax>
      <email>patrick.manning@otagodhb.govt.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Liz Berry</name>
      <address>9th Floor
Dunedin Hospital
201 Great King Street
Dunedin 9016</address>
      <phone>+64 3 4747727</phone>
      <fax>+64 3 4747728</fax>
      <email>liz.berry@otago.ac.nz</email>
      <country>New Zealand</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>